Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
156-B7-100
156-B7-01M
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Bioactivity
1 Image
Product Details
Citations (10)
FAQs
Supplemental Products
Reviews (19)

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2‑10 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein
Human PD-L1
(Phe19-Thr239)
Accession # Q9NZQ7
DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Phe19
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
52 kDa (monomer)
SDS-PAGE
70-75 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

156-B7

Formulation Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Image

Bioactivity Bioactivity View Larger

Recombinant Human PD-L1/B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2-10 μg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PD-L1/B7-H1

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on
inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).

References
  1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  2. Dong, H. et al. (1999) Nat. Med. 5:1365.
  3. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  4. Tamura, H. et al. (2001) Blood 97:1809.
  5. Chen, L. et al. (2007) J. Immunol. 178:6634.
  6. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  7. Tsushima, F. et al. (2007) Blood 110:180.
  8. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  9. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  10. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  11. Dong, H. et al. (2002) Nat. Med. 8:793.
  12. Azuma, T. et al. (2008) Blood 111:3635.
  13. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  14. Park, J.-J. et al. (2010) Blood 116:1291.
  15. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  16. Herold, M. et al. (2015) J. Immunol. 195:3584.
Long Name
Programmed Death Ligand 1
Entrez Gene IDs
29126 (Human); 60533 (Mouse); 499342 (Rat); 484186 (Canine); 102145573 (Cynomolgus Monkey)
Alternate Names
B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

10 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
    Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
    JCI Insight, 2018;3(19):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  2. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice
    Authors: E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston
    Mol. Cancer Ther, 2017;0(0):.
    Species: N/A
    Sample Types: Protein
    Applications: Bioassay
  3. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
    Authors: UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl
    Anticancer Res., 2017;37(4):1947-1955.
    Applications: ELISA (Standard)
  4. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
    Sci Rep, 2016;6(0):36722.
    Species: Human
    Sample Types: Protein
    Applications: ELISA (Standard)
  5. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
    Authors: Robert L Ferris
    Oncoimmunology, 2016;5(10):e1200778.
    Applications: Bioassay
  6. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
    Authors: Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R
    Cancer Res, 2015;75(3):508-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
    Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
    PLoS ONE, 2014;9(12):e113396.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  8. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells.
    Authors: Chinnadurai R, Copland I, Patel S, Galipeau J
    J Immunol, 2014;192(4):1491-501.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
    Authors: Steidl C, Shah SP, Woolcock BW
    Nature, 2011;471(7338):377-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
    Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
    J. Immunol., 2006;177(12):8844-50.

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Average Rating: 4.9 (Based on 19 Reviews)

5 Star
94.74%
4 Star
0%
3 Star
5.26%
2 Star
0%
1 Star
0%

Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/06/2018
Application: Stem/Immune cell maintenance or differentiation

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 10/24/2018
Application: Cell Adhesion

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 10/12/2018
Application: Enzymatic activity in vitro

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 09/28/2018
Application: CellProlif

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 08/26/2018
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 04/12/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/30/2018
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/15/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/11/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 02/07/2018
Application: Binding assay/Protein-protein interaction
Reason for Rating: Binding observed.

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/18/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/06/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/01/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/27/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/18/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/20/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/20/2017
Application: Cell Adhesion

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/14/2017
Application: SPR assay for Kinetics between PDL-1 and AntiPDL-1 Antibody

SPR experiment


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 05/23/2017

Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.